dr. david spigel discusses the evolving non-small cell lung cancer treatment landscape
Published 11 years ago • 273 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:34
dr. spigel discusses pd-l1 antibody for non-small cell lung cancer patients - sarah cannon
-
4:34
dr. david spigel discusses diagnosis, treatments, and scientific advances for lung - hln
-
1:26
david spigel, md, on how results from the flaura study impact treatment selection in lung cancer
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
1:41
dr. spigel discusses mpdl3280a in lung cancer
-
19:33
cancer survivor story: how i got diagnosed with lung cancer (1/3) | montessa lee | the patient story
-
4:01
how to spot red flag warning signs & symptoms of lung cancer... doctor o'donovan explains
-
4:44
understanding non-small cell lung cancer
-
1:26
dr. spigel discusses results from a phase iii study exploring eribulin in nsclc
-
4:42
dr. david spigel discusses risk factors, screening, and breakthroughs for lung cancer - hln
-
13:04
esmo 2019: dr. spigel highlights progress in lung cancer
-
1:27
dr. schenk on the evolving treatment landscape in lung cancer
-
1:32
dr. spigel on checkmate-331 trial for sclc
-
4:47
treating non–small cell lung cancer with an egfr exon 20 insertion
-
1:05
dr. aggarwal on emerging treatment approaches in alk nsclc
-
1:30
dr. spigel on the rationale behind the pacific trial
-
1:54
dr. langer discusses the impact of targeted therapy in nsclc
-
0:59
upcoming trends in the lung cancer treatment landscape
-
7:44
next-generation targeted therapies in non-small cell lung cancer
-
6:42
pseudoprogression with checkpoint inhibitors in non-small cell lung cancer
-
2:03
dr. corey langer discusses treating locally advanced non-small cell lung cancer
-
1:15
dr. rudin discusses the success of immunotherapy in sclc